(OPCH) Option Care Health - Overview
Stock: Infusion, Nutrition, Immunotherapy, Neurological
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 29.8% |
| Relative Tail Risk | -4.88% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.30 |
| Alpha | 3.14 |
| Character TTM | |
|---|---|
| Beta | 0.340 |
| Beta Downside | 0.264 |
| Drawdowns 3y | |
|---|---|
| Max DD | 38.67% |
| CAGR/Max DD | 0.15 |
Description: OPCH Option Care Health January 08, 2026
Option Care Health, Inc. (NASDAQ: OPCH) delivers a broad portfolio of home- and alternate-site infusion therapies across the United States, covering anti-infectives, cardiac failure treatments, parenteral and enteral nutrition, immunoglobulins, chronic inflammatory diseases (e.g., Crohn’s, rheumatoid arthritis), neurological disorders (e.g., Duchenne muscular dystrophy, multiple sclerosis), bleeding disorders, high-risk pregnancy care, and supportive services such as pain management, chemotherapy, and respiratory medication administration. The company sources patients primarily through referrals from physicians, hospital discharge planners, health-maintenance organizations (HMOs), and preferred provider organizations (PPOs), and is headquartered in Bannockburn, Illinois.
Recent SEC filings (Q2 2024) show OPCH generated $1.03 billion in revenue, a 12% year-over-year increase driven by a 15% rise in home-infusion patient volume and higher reimbursement rates for specialty drugs. The business benefits from macro trends such as the U.S. shift toward outpatient care (home-health market projected to grow > 7% CAGR through 2028) and an aging population that expands demand for chronic-disease management. However, the companys margins remain sensitive to payer mix changes and drug pricing volatility, which have historically introduced ± 3% swings in adjusted EBITDA margin.
If you want a data-rich, independent perspective on OPCH’s valuation and risk profile, consider reviewing the analyst tools available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 209.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -1.41 > 1.0 |
| NWC/Revenue: 8.30% < 20% (prev 11.69%; Δ -3.39% < -1%) |
| CFO/TA 0.07 > 3% & CFO 258.7m > Net Income 209.2m |
| Net Debt (966.4m) to EBITDA (458.4m): 2.11 < 3 |
| Current Ratio: 1.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (164.6m) vs 12m ago -4.27% < -2% |
| Gross Margin: 19.41% > 18% (prev 0.21%; Δ 1920 % > 0.5%) |
| Asset Turnover: 160.1% > 50% (prev 139.3%; Δ 20.79% > 0%) |
| Interest Coverage Ratio: 3.35 > 6 (EBITDA TTM 458.4m / Interest Expense TTM 117.2m) |
Altman Z'' 2.80
| A: 0.13 (Total Current Assets 1.28b - Total Current Liabilities 823.9m) / Total Assets 3.48b |
| B: 0.24 (Retained Earnings 818.4m / Total Assets 3.48b) |
| C: 0.11 (EBIT TTM 392.7m / Avg Total Assets 3.45b) |
| D: 0.39 (Book Value of Equity 823.9m / Total Liabilities 2.12b) |
| Altman-Z'' Score: 2.80 = A |
Beneish M -2.86
| DSRI: 0.96 (Receivables 474.5m/429.0m, Revenue 5.53b/4.78b) |
| GMI: 1.07 (GM 19.41% / 20.76%) |
| AQI: 1.07 (AQ_t 0.59 / AQ_t-1 0.55) |
| SGI: 1.16 (Revenue 5.53b / 4.78b) |
| TATA: -0.01 (NI 209.2m - CFO 258.7m) / TA 3.48b) |
| Beneish M-Score: -2.86 (Cap -4..+1) = A |
What is the price of OPCH shares?
Over the past week, the price has changed by +0.83%, over one month by +6.18%, over three months by +26.18% and over the past year by +9.10%.
Is OPCH a buy, sell or hold?
- StrongBuy: 6
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the OPCH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 39.8 | 16.5% |
| Analysts Target Price | 39.8 | 16.5% |
| ValueRay Target Price | 34.8 | 1.9% |
OPCH Fundamental Data Overview February 03, 2026
P/E Forward = 19.9601
P/S = 0.9977
P/B = 3.9594
P/EG = 1.6051
Revenue TTM = 5.53b USD
EBIT TTM = 392.7m USD
EBITDA TTM = 458.4m USD
Long Term Debt = 1.16b USD (from longTermDebt, last quarter)
Short Term Debt = 30.3m USD (from shortTermDebt, last quarter)
Debt = 1.28b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 966.4m USD (from netDebt column, last quarter)
Enterprise Value = 6.48b USD (5.52b + Debt 1.28b - CCE 309.8m)
Interest Coverage Ratio = 3.35 (Ebit TTM 392.7m / Interest Expense TTM 117.2m)
EV/FCF = 26.11x (Enterprise Value 6.48b / FCF TTM 248.3m)
FCF Yield = 3.83% (FCF TTM 248.3m / Enterprise Value 6.48b)
FCF Margin = 4.49% (FCF TTM 248.3m / Revenue TTM 5.53b)
Net Margin = 3.78% (Net Income TTM 209.2m / Revenue TTM 5.53b)
Gross Margin = 19.41% ((Revenue TTM 5.53b - Cost of Revenue TTM 4.46b) / Revenue TTM)
Gross Margin QoQ = 19.02% (prev 19.00%)
Tobins Q-Ratio = 1.86 (Enterprise Value 6.48b / Total Assets 3.48b)
Interest Expense / Debt = 5.62% (Interest Expense 71.7m / Debt 1.28b)
Taxrate = 24.87% (17.2m / 69.0m)
NOPAT = 295.0m (EBIT 392.7m * (1 - 24.87%))
Current Ratio = 1.56 (Total Current Assets 1.28b / Total Current Liabilities 823.9m)
Debt / Equity = 0.94 (Debt 1.28b / totalStockholderEquity, last quarter 1.36b)
Debt / EBITDA = 2.11 (Net Debt 966.4m / EBITDA 458.4m)
Debt / FCF = 3.89 (Net Debt 966.4m / FCF TTM 248.3m)
Total Stockholder Equity = 1.37b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.06% (Net Income 209.2m / Total Assets 3.48b)
RoE = 15.29% (Net Income TTM 209.2m / Total Stockholder Equity 1.37b)
RoCE = 15.56% (EBIT 392.7m / Capital Employed (Equity 1.37b + L.T.Debt 1.16b))
RoIC = 11.84% (NOPAT 295.0m / Invested Capital 2.49b)
WACC = 6.62% (E(5.52b)/V(6.79b) * Re(7.17%) + D(1.28b)/V(6.79b) * Rd(5.62%) * (1-Tc(0.25)))
Discount Rate = 7.17% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.77%
[DCF Debug] Terminal Value 85.86% ; FCFF base≈266.2m ; Y1≈327.1m ; Y5≈551.8m
Fair Price DCF = 75.29 (EV 12.92b - Net Debt 966.4m = Equity 11.95b / Shares 158.7m; r=6.62% [WACC]; 5y FCF grow 24.45% → 2.90% )
EPS Correlation: 20.12 | EPS CAGR: -39.48% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.80 | Revenue CAGR: 12.35% | SUE: 0.98 | # QB: 8
EPS next Quarter (2026-03-31): EPS=0.41 | Chg30d=+0.000 | Revisions Net=-3 | Analysts=8
EPS next Year (2026-12-31): EPS=1.87 | Chg30d=-0.010 | Revisions Net=-5 | Growth EPS=+8.5% | Growth Revenue=+5.9%